Phase I trial of continuous Taxotere, Adriamycin, and cyclophosphamide with G-CSF (conTAC).

被引：0
|
作者：
Budd, GT [1 ]
Peereboom, D [1 ]
Weiss, P [1 ]
Elson, P [1 ]
机构：
[1] Cleveland Clin Fdn, Ctr Canc, Cleveland, OH 44195 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
354
引用
收藏
页码：270 / 270
页数：1
相关论文
共 50 条
  • [41] Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?
    Dazzi, C
    Cariello, A
    Rosti, G
    Argnani, M
    Sebastiani, L
    Ferrari, E
    Zornetta, L
    Monti, G
    Nicoletti, P
    Baioni, M
    Salvucci, M
    Scarpi, E
    Marangolo, M
    LEUKEMIA & LYMPHOMA, 2000, 39 (3-4) : 301 - 310
  • [42] G-CSF alone or cyclophosphamide plus G-CSF allow comparable mobilization of PBPC in patients affected with lymphoma and not heavily pre-treated.
    Milone, GFG
    Leotta, S
    Mercurio, S
    Indelicato, F
    Moschetti, G
    Di Raimondo, F
    Tornello, A
    Consoli, U
    Guido, G
    Giustolisi, R
    BLOOD, 2002, 100 (11) : 828A - 829A
  • [43] PERIPHERAL BLOOD STEM CELL MOBILIZATION USING G-CSF ALONE FOR MM WITH THE MINIMAL RESIDUAL DISEASE COMPARED TO CYCLOPHOSPHAMIDE PLUS G-CSF
    Jang, J. E.
    Hyun, S. Y.
    Hwang, D. Y.
    Kim, Y. D.
    Kim, S. J.
    Cheong, J. W.
    Min, Y. H.
    Kim, J. S.
    HAEMATOLOGICA, 2012, 97 : 609 - 609
  • [44] Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia
    Becker, Pamela S.
    Estey, Elihu
    Petersdorf, Stephen
    Hendrie, Paul C.
    Pagel, John M.
    Stirewalt, Derek
    Shustov, Andrei
    Storer, Barry E.
    Appelbaum, Frederick R.
    BLOOD, 2008, 112 (11) : 1018 - 1018
  • [45] Randomized study of CD34+ peripheral stem cells mobilization by G-CSF compared to G-CSF plus GM-CSF after cyclophosphamide.
    Quittet, P
    Legouffe, E
    Lopez, E
    Fegueux, N
    Klein, B
    Rossi, JF
    BONE MARROW TRANSPLANTATION, 1998, 21 : S13 - S13
  • [46] A Phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer
    Harada, T.
    Hamada, A.
    Shimokawa, M.
    Takayama, K.
    Kudoh, S.
    Maeno, K.
    Saeki, S.
    Miyawaki, H.
    Moriyama, A.
    Nakagawa, K.
    Nakanishi, Y.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (02) : 127 - 133
  • [47] Vinorelbine and cyclophosphamide plus G-CSF as mobilisation regimen for patients with multiple myeloma
    Palmieri, S
    Pocali, B
    Copia, C
    Schiavone, EM
    Annunziata, M
    Viola, A
    Ferrara, F
    BONE MARROW TRANSPLANTATION, 2004, 33 : S354 - S354
  • [48] G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse
    Hadaya, K
    Kared, H
    Masson, A
    Chatenoud, L
    Zavala, F
    JOURNAL OF AUTOIMMUNITY, 2005, 24 (02) : 125 - 134
  • [49] COMPARISON OF PERIPHERAL BLOOD STEM CELL (PBSC) MOBILIZATION WITH G-CSF ALONE VS G-CSF WITH CYCLOPHOSPHAMIDE POST VCD INDUCTION IN MULTIPLE MYELOMA
    Chua, C. C.
    Lim, H. Y.
    Chai, K. L.
    Ong, J.
    Sim, S.
    Dickinson, M.
    Campbell, P.
    Hempton, J.
    King, H.
    Dowsing, C.
    Bergin, K.
    Muir, S.
    Gibbs, S.
    Grigg, A.
    HAEMATOLOGICA, 2016, 101 : 541 - 542
  • [50] Leukapheresis products in multiple myeloma: Lower tumor load after mobilization with cyclophosphamide plus G-CSF compared to G-CSF in steady-state.
    Cremer, FW
    Kiel, K
    Wallmeier, M
    Haas, R
    Goldschmidt, H
    Moos, M
    BLOOD, 1997, 90 (10) : 435 - 435
12345